On October 31, Shanghai Kejun Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Kejun Pharmaceutical") announced the completion of its B+ round of phased financing. This round of financing was led by Guoxin Innovation Equity, and other major investors included Aeon Group and Infinity Capital, and the original investor Honghai Capital also continued to make additional investments. Qidian Capital served as the financial advisor for this round of financing and will continue to provide financing services to Kejun Pharmaceutical in the future.
Kejun Pharmaceutical stated that the funds raised from this financing will be used to accelerate the clinical development of CG-0255, a core product in the cardiovascular field.

About Kejun Pharmaceutical

Kejun Pharmaceutical was established in Zhangjiang, Shanghai in 2018, focusing on the treatment of cardiovascular and cerebrovascular diseases and antiviral diseases, and focusing on the research and development of small molecules and nucleic acid drugs. At present, Kejun Pharmaceutical has built a world-leading targeted prodrug and nucleic acid drug technology platform, and its pipeline has a number of innovative drugs with global independent intellectual property rights and huge market potential.
In the cardiovascular field, Kejun Pharmaceutical's core pipeline antiplatelet drug CG-0255 has made the fastest progress. According to public information, CG-0255 is a new generation of P2Y12 antiplatelet drugs, which is developed for antiplatelet treatment of cardiovascular and cerebrovascular diseases. Previously, CG-0255 has completed phase I clinical trials in both injection and oral dosage forms in the United States, and related results have been invited to be released at the 2023 AHA and 2024 ESC annual meetings. At present, Kejun Pharmaceuticals is actively promoting the registration clinical stage of this variety in the United States, and has also submitted a clinical development application in China.

In the field of antiviral, Kejun Pharmaceuticals has also made remarkable achievements. Among them, the RNA polymerase inhibitor CG-0980 is a small molecule direct antiviral drug with broad-spectrum antiviral activity. It is developed for the indications of broad-spectrum respiratory RNA virus infection and is suitable for most people for the treatment of respiratory virus infection and the clinical potential needs of post-exposure prevention of close contact. In addition, Kejun Pharmaceuticals' multiple pipelines such as functional cure of chronic hepatitis B have also made breakthrough progress and have shown broad prospects for clinical application.

https://news.yaozh.com/archive/44475.html